CN104161763B - A kind of pharmaceutical composition is as preparing the application treated in dermatitis and eczema - Google Patents
A kind of pharmaceutical composition is as preparing the application treated in dermatitis and eczema Download PDFInfo
- Publication number
- CN104161763B CN104161763B CN201310186782.8A CN201310186782A CN104161763B CN 104161763 B CN104161763 B CN 104161763B CN 201310186782 A CN201310186782 A CN 201310186782A CN 104161763 B CN104161763 B CN 104161763B
- Authority
- CN
- China
- Prior art keywords
- eczema
- dermatitis
- pharmaceutical composition
- oxymatrine
- glycyrrhizic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Abstract
The present invention relates to kushenins（Oxymatrine, matrine）Further include glycyrrhizic acid matrine salt and glycyrrhizic acid kushenin salt with the derivative of the pharmaceutically acceptable form or the two of glycyrrhizic acid or the two and containing the medicine box of these compositions, is used to prepare the application of prevention dermatitis and eczema.
Description
Technical field
The invention belongs to field of medicaments, it is related to a kind of pharmaceutical composition and is used to prepare answering in prevention and treatment dermatitis and eczema
With.Described pharmaceutical composition contains kushenin（Oxymatrine, matrine, Iosmatrine）With glycyrrhizic acid or the pharmacy of the two
The derivative of upper acceptable form or the two and the medicine box containing these compositions include additionally glycyrrhizic acid matrine salt
And glycyrrhizic acid kushenin salt.
Background technology
It is well known that dermatitis and eczema is the common disease of dept. of dermatology, the cause of disease and pathogenesis of dermatitis and eczema
Not yet clear, the cause of disease is considerably complicated, and majority causes for allergy, it is abnormal anti-as caused by the interaction of various internal and external factors
It answers.But some dermatitis and eczemas are then unrelated with allergy.The change of patient's reaction is often related to various factors, some are also
It is unclear, still need to be studied from now on.（One）Inherent cause：Certain form of eczema has close relationship, eczema patients with heredity
Often there is certain allergic constitution, have anaphylactia medical history in family.The allergy such as easy being in contact property dermatitis, drug response
Property disease；（Two）Environmental factor；The influence of environmental factor is primarily referred to as increasing and complex environment allergen；（Three）Sense
Dye factor：Certain eczemas are related with the infection of microorganism.These microorganisms include staphylococcus aureus, chlosma, air source
Property fungi such as Alternaria, branch spore be mould, point mould, aspergillus fumigatus, reaping hook are mould, penicillium chrysogenum, aspergillus niger and bread mold etc.；（Four）
Dietary factor：The food variety of the mankind is extremely more, generally can be divided into plant, animal class, mineral substance, is also passed through in the food in modern age
Often apply some chemically synthesized foods such as saccharin, acetic acid, citric acid, essence, synthetic dyestuffs etc..These foods can cause food
Allergy, so as to cause the generation of eczema；（Five）Drug factors：Some drugs can cause eczema；（Six）Other factors：
The generation of eczema still by psychoneurals factor and the daylight such as depressed, tired, worried, nervous, excited, insomnia, ultraviolet light,
The weathers such as cold, moist, dry, friction, physical factor induce eczema or eczema are made to aggravate.In addition chronic gastrointestinal diseases, stomach and intestine
The factors such as road dysfunction, malnutrition, chronic alcoholism, enterozoon and dysbolism, endocrine disorder are all
It is the reason of eczema occurs.The external factor of eczema may be various physicochemical irritations, as solarization easily induces eczema；Cold can make skin
Skin drying chap；When hot, skin hidrosis is easily impregnated and itch and scratches.Soap, detergent are used in life too much
Deng the barrier action of skin can be made to be destroyed, lose its defencive function, certain stimulants or sensitizer is made to enter in vivo and lead
Cause the generation of eczema.Eczema belongs to a kind of delayed allergy, and in pathogenic process, mast cell plays a key role.
On the one hand mast cell degranulation causes classical anaphylactic type, on the other hand the acidophil granules further through its release are thin
Born of the same parents, chemotactic factor (CF), leukotrienes and its arachidonic acid spread out capable biology etc., in original degranulation cell after 4-8 hours
Position causes the infiltration of polymorphonuclear cell again；After 24-48 hours, polymorphonuclear cell makes its leaching further through the inhibiting factor of its release
Profit is gradually replaced by monocyte infiltration, and delayed metamorphosis is collectively formed instead with macrophage and fibroblast infiltration
It answers, the irritability that tissue damage makes mucous membrane is caused to improve, be easy to react to specificity and nonspecific stimulation, cause eczema
Recurrent exerbation.
Currently, there is no good method, common therapy to have following several dermatitis and eczema：1, base therapy：（1）
Avoid induction and Acute aggravated factors；（2）Restore and keep skin barrier function.2, drug therapy coordinates local treatment：（1）Sugared cortex
Hormone：Local interruption external application glucocorticoid, and coordinate moisturizing moisturizer etc., it is the usual therapy of current treatment dermatitis and eczema.
Long-time service can cause certain skin adverse reaction（Such as atrophoderma, telangiectasis, striae distensae, hirsutism, sugared cortex
Hormonal acne, bacterium infection, purpura etc.）, long-term large-area applications can also cause systemic adverse reaction sometimes（On iatrogenic kidney
Gland cortex hormone function is complete, Cushing syndrome, Spirit nerve symptoms of disease, glaucoma, cataract and the confusion of the menstrual cycle etc.）.（2）Calcium tune
Neural inhibitors of phosphatases：Such drug includes Tacrolimus paste and Elidel emulsifiable paste, has good efficacy to dermatitis and eczema,
With stronger selective anti-inflammatory effect, relatively long time all site of pathological change can be used for.Adverse reaction is mainly used
After medicine the local short time burn and excitement, apparent system adverse reaction is not yet found, also without the bad of glucocorticoid
Reaction.（3）Topical antibiotic preparation：Since bacterium or fungi can induce or add by generation super antigen or as allergen
Grave illness feelings, while using glucocorticoid, when especially treatment has exudative skin lesion, early stage, which adds, uses antibacterium or antimycotic
Drug can be conducive to control the state of an illness, but should avoid being used for a long time.（4）Antipruritic：5 % Doxepin Hydrochloride Cream in Animals non-stay body anti-inflammatory agent
Object can effectively mitigate rash and itch symptom in a short time, and can replace with Donisolone or Calcineurin inhibitors makes
With.（5）Other：According to the difference of the cleer and peaceful skin lesion of disease, soak, zinc oxid oil may be selected（Paste）Agent, tar, Pityrol etc..3、
Drug therapy coupled system is treated：（1）Antihistamine and cell membrane stability agent：It may be selected according to the different state of an illness and medication object
The first generation or second generation antihistamine.（2）Anti-infectives：For sick clear serious（Especially there is exudation person）Or had proven to after
The patient for sending out bacterium or fungal infection, can give anti-infectives in short term.（3）Glucocorticoid：It can to the patient being in a bad way
Give the short-term medication of small.Should gradually be reduced, be discontinued in time after sb.'s illness took a favorable turn, so as not to be used for a long time the adverse reaction that brings or
The too fast and pathogenic feelings that are discontinued are bounced.（4）Allergen specific desensitization therapy：Be by it is not being avoided that and through Skin-test or other
The main antigenic substance that method confirms or suspects, is made certain density leachate, with gradual ascending-dose and the side of concentration
Method is injected, and by giving patient injection specific antigen repeatedly, promotes to generate corresponding antibody in vivo.（5）Immunosuppressor：
For being in a bad way and the uppity patient of routine treatment can take the circumstances into consideration to select ring born of the same parents element, imuran and mycophenolate mofetil
Deng.（6）Leukotriene modifiers：Leukotriene antagonist can be divided into（LTAA）And leukotriene inhibitors.By to cell surface white three
The antagonism of alkene receptor, the sensitization and proinflammatory effect of the cysteamine acyl leukotriene that inhibition mast cell and acidophil release.（7）
Other：Tranilast, glycyrrhizic acid and multi-vitamins etc. are alternatively used for the treatment of dermatitis and eczema, there is auxiliary therapeutic action interference
Element-γ, being treated for dermatitis and eczema effectively, but often to need longer-term to maintain medication.4, Chinese traditional treatment：According to clinical symptoms and
Sign carries out tcm treatment according to syndrome differentiation.5, physiotherapy：Ultraviolet light, phototherapy.There are many above-mentioned therapy, but have its limitation
And adverse reaction, as the long-term external application of glucocorticoid can cause certain skin adverse reaction（As atrophoderma, capillary expand
, striae distensae, hirsutism, patients with glucocorticoid acne, bacterium infection, purpura etc.）, long-term large area external application or it is oral cause be
The adverse reaction of system property（Iatrogenic adrenal insufficiency, Cushing syndrome, Spirit nerve symptoms of disease, glaucoma, cataract and
The confusion of the menstrual cycle etc.）.
Since the dermatitis and eczema cause of disease is complicated, although there are many therapy, there are its limitation and adverse reaction, treatment effect
Fruit is nor highly desirable.
Matrine is that have hormone-like effect and the strength anti-inflammatory agent without hormone side effect, research have shown that mainly to inhibit white with it
Cell migration, the synthesis or release stablizing lysosome membrane, promote radicals scavenging, inhibiting the inflammatory mediators such as histamine and lymphokine
And inhibit inflammatory activity related；Oxymatrine has stronger immunoregulation effect, can by antibody level to host, exempt from
The influence of the variation of epidemic disease cell, cell factor and other inflammatory mediators plays its anti-inflammatory effect；But effective extraction of kuh-seng
Object or matrine arrange side effects, the patients for causing urine volume excessive such as sodium in clinic there are diuresis to be used.Glycyrrhizic acid has anti-
The effects that inflammation, antiallergic action, antiviral, liver protection, but the steroids sample effect of glycyrrhizic acid, long-term a large amount of oral Radix Glycyrrhizaes it is effective
Component extract or glycyrrhizic acid and its derivative can make patient there are water-sodium retention, hypertension and Diagnostic values etc. serious bad anti-
It answers.
For the present invention by experiment, provide has adduction synergistic effect and toxic side effect is lower completely new for dermatitis and eczema
Pharmaceutical composition, and its prepare for treating the application in dermatitis and eczema.
Invention content
This invention people is by testing it has surprisingly been found that kushenin（Oxymatrine, matrine）Or derivatives thereof and it is sweet
The pharmaceutical composition of oxalic acid or derivatives thereof can provide particularly advantageous treatment dermatitis and eczema effect, apparent without observing
Side effect.And this pharmaceutical composition is particularly suitable for treating dermatitis and eczema, including neurodermatitis, eczema（Acute, sub- urgency
Property and chronic eczema）, atopic dermatitis, seborrhea, cutaneous pruritus, contact dermatitis, nettle rash, chronic moss sample skin
Inflammation, autosensitization dermatitis, dermatitis infectiosa eczematoides, stasis dermatitis, pruigo, prurigo nodularis, photosensitive dermatitis.It is this
Pharmaceutical composition spy can also combine the technology of existing treatment dermatitis and eczema such as：Ultraviolet light irradiation, red blue light illumination, antihistamine
Object and external-applied ointment application.
The object of the present invention is to provide a kind of pharmaceutical composition for treating dermatitis and eczema, affiliated pharmaceutical composition includes sequence
Give or give pharmaceutically acceptable amount simultaneously or medicine effective dose kushenin or derivatives thereof and glycyrrhizic acid or its spread out
Biology, especially pharmaceutical acceptable form or its pharmaceutical salts.Further include glycyrrhizic acid matrine salt and glycyrrhizic acid kushenin salt.
The weight proportion of kushenin or derivatives thereof and glycyrrhizic acid or derivatives thereof is 10 in composition：1~1：10, preferably
Be 5：1~1：5, more preferable 5：1~1：2.Wherein kushenin or derivatives thereof content be 50 ~ 2000mg, further preferably 100
~ 1500mg, more preferably 300 ~ 1000mg；Glycyrrhizic acid or derivatives thereof content be 30 ~ 2000mg, further preferably 30 ~
1500mg, more preferably 100 ~ 1000mg.
It is administered simultaneously including giving kushenin or derivatives thereof and glycyrrhizic acid or derivatives thereof, or by each activating agent
Independent preparation is substantially simultaneously administered.It refers in chronological sequence giving kushenin according to clinical treatment or it spreads out that sequence, which is given,
Biology, glycyrrhizic acid or derivatives thereof.Kushenin that the present invention provides or derivatives thereof and glycyrrhizic acid or derivatives thereof drug scalar,
It is provided about compound itself, such as the kushenin of 100mg hydrochloride forms refers to the hydrochloride containing 50mg kushenins
Amount.
In the present invention, active medicine is administered preferably in the form of pharmaceutical composition, and this composition may include a variety of medicines
Object or only a kind of drug.Described pharmaceutical composition can be by by kushenin of above-mentioned content range or derivatives thereof and glycyrrhizic acid
Or derivatives thereof after appropriate pharmaceutically acceptable form is mixed with acceptable carrier, according to the preparation of the pharmaceutical preparation of routine
It is prepared by method.
Kushenin or derivatives thereof and glycyrrhizic acid or derivatives thereof are to distinguish in the form of pharmaceutical acceptable（Including medicine
Acceptable salt, ester and solvate on）As pharmaceutically active agents administration.The kushenin or derivatives thereof of the present invention includes
Kushenin, oxymatrine, matrine, Iosmatrine or its officinal salt（Including hydrochloride, sulfate, acetate, phosphoric acid
Salt, fumarate and various amino-acid salts）.Glycyrrhizic acid or derivatives thereof includes glycyrrhizic acid, glycyrrhizin, Isoglycyrrhiza acid, different
Glycyrrhetate, glycyrrhetate etc., glycyrrhetate include that glycyrrhizin can medication salt, ammonium glycyrrhizinate, diammonium glycyrrhizinate, glycyrrhizic acid
Glycosides, sodium glycyrrhetate, potassium glycyrrhizana and Radix Glycyrrhizae acid calcium salt etc..Further include glycyrrhizic acid matrine salt and glycyrrhizic acid kushenin salt.
By the quality proportioning and corresponding auxiliary material can be added in described pharmaceutical composition, be made and be suitble to oral medication, note
Penetrate the dosage form of administration, percutaneous dosing, transmucosal absorption administration or other dosage forms.Described pharmaceutical composition can be prepared into greatly
Or the dosage forms such as the injection of low capacity, freeze-dried powder, aseptic powder packing, can also be tablet, capsule, pulvis, dripping pill, micro-
Ball, particle, pastille, suppository, oral solution or sterile parenteral solutions or suspension formulation form or other dosage forms such as emulsion, paste
Deng.Oral liquid can be the forms such as emulsion, syrup, can also be used as dry products presence, using it is preceding again use water or its
He reconstitutes suitable carrier.Auxiliary material includes（It is not limited to）Physiologically acceptable pharmaceutical excipient and pharmaceutic adjuvant.Wherein
Pharmaceutic adjuvant includes one or more of sodium chloride, mannitol, PVP K30, glucose, lactose and combinations thereof.
In order to reach the consistency of administration, the present composition is preferably unit dose form.
For oral medication, containing pharmaceutically conventional excipient such as adhesive, for example (,) it is syrup, Arabic gum, bright
Glue, sorbierite, tragacanth, polyvinylpyrrolidone, hydroxypropyl methylcellulose, dextrin, polyethylene glycol etc.；Filler, such as lactose,
Sugar, cornstarch, calcium phosphate, sorbierite, glycine etc.；Tableting lubricant, such as magnesium stearate, polyethylene glycol etc.；Disintegrant,
Such as starch, polyvinylpyrrolidone, Explotab or microcrystalline cellulose；Pharmaceutically acceptable wetting agent, such as 12
Sodium alkyl sulfate etc.；Suspending agent, such as sorbierite, syrup, methylcellulose, gelatin, hydroxyethyl cellulose, carboxymethyl cellulose
Element, aluminum stearate gel or hydrogenation eat ester etc.；Emulsifier, such as lecithin, anhydro sorbitol-oleate, Arabic gum
Deng；Anhydrous carrier（It may include edible oil）, such as apricot kernel oil, evaporating coconut oil or oily ester；Preservative, such as para hydroxybenzene
Methyl formate, propyl ester, sorbic acid etc.；Corrigent and sweetener, such as rebaudioside, Aspartame, Steviosin, xylitol, peppermint
Alcohol, flavoring orange essence etc.；Colorant etc. can also be added.Preparation method uses the preparation method of this field routine.
For parenteral, especially injection, unit is prepared respectively at sterile carrier using two kinds of active components
Liquid dosage form, and be suspended or dissolved in carrier according to concentration used.It, can be molten by active constituent when preparing liquid
Solution is filled into container is sealed later in water for injection and filtration sterilization.Advantageously, in order to be suitble to intravenous injection can be with
The common adjuvant of injection such as preservative, buffer, acidity-basicity regulator, Osmolyte regulator, solubilizer, stabilization is added
Agent, antioxidant etc..
In addition can also conventionally by pharmaceutical composition single active ingredient or pharmaceutical composition slow control is made
Release formulation, such as sustained release pellet or controlled release micro pill.
Preferably unit dose is made with the amount with relevant date appropriate dosage in described pharmaceutical composition.It can be with daily administration 1 ~ 6
It is secondary, but be most preferably administered once daily（Drug administration by injection）Or 3 times（Oral medication and topical administration）.
According to the difference of administering mode and formulation requirements, in the composition kushenin or derivatives thereof and glycyrrhizic acid or its spread out
The sum of biological content can be the 0.1% ~ 99% of total amount, preferably 1% ~ 60%.
The present invention is by the way that experimental results demonstrate the pharmaceutical compositions of kushenin or derivatives thereof and glycyrrhizic acid or derivatives thereof
Treating dermatitis and eczema has especially significant effect, toxic side effect lower.
Specific implementation mode
We illustrate the present invention in conjunction with the embodiments below.Following embodiment is merely to illustrate the technical side of the present invention
Case is not intended to limit the present invention.
Embodiment 1
The comparison that oxymatrine, glycyrrhizic acid and combinations thereof act on Mouse Acute Toxicity
Kunming mice is randomly divided into Normal group and test medicine group, every group ten, half male and half female.Except Normal group
Outside, test medicine group is injected intraperitoneally respectively（ip）The composition of large dosage of oxymatrine, glycyrrhizin and two kinds of components is primary,
It is observed continuously 7 days, records death time and the death toll of animal.
The results show that when the dosage of oxymatrine is 950mg/kg, there is larger toxicity, 9 death in 10 mouse,
When glycyrrhizin dosage is 950mg/kg, 2 death in 10 mouse, and Oxymatrine subtracts：Glycyrrhizin is 1：1 and share agent
Amount is 950mg/kg and kushenin：Glycyrrhizin is 2：1 and share dosage be 950mg/kg when, no animal dead, Oxymatrine
Subtract：Glycyrrhizin is 3：1 and share dosage be 950mg/kg when, 2 animal deads, illustrate oxymatrine and glycyrrhizin into
Row proportioning combination, toxicity is substantially reduced, and oxymatrine, glycyrrhizin press 1：1 and 2：1, which matches its toxicity, is less than 3：1 matches
Than.
1 oxymatrine of table, glycyrrhizic acid and combinations thereof（Ip is primary）Comparison to Mouse Acute Toxicity effect
| Group | Dosage（mg/kg） | Death toll/sum |
| Normal group | 0 | 0/10 |
| It is bitter | 950 | 9/10 |
| It is sweet | 950 | 2/10 |
| It is bitter+sweet（1：1） | 950 | 0/10 |
| It is bitter+sweet（2：1） | 950 | 0/10 |
| It is bitter+sweet（3：1） | 950 | 2/10 |
Remarks：" hardship "：Indicate oxymatrine；" sweet "：Indicate glycyrrhizin
Embodiment 2
The effect of compound glycyrrhizin co-oxidation Sophorcarpidine Treating universal eczema, is observed
1 data and method
1.1 clinical data clinical diagnosises meet universal eczema patient, and clinical diagnosis meets acute eczema, subacute wet
40 patients of rash or chronic eczema acute attack, man 20, female 20,20 ~ 50 years old age did not received to control in January
It treats, the serious viscera disease such as no liver and kidney dysfunction, no active pulmonary tuberculosis, high blood pressure, diabetes, cataract medical history are picked
Except the gestational period, women breast-feeding their children.Patient is randomly divided into four groups：Oxymatrine Treating group（A groups）, SNMC in Treatment
Group（B groups）, oxymatrine combine SNMC in Treatment group（C groups）, control group（D groups）, every group ten, men and women is fifty-fifty.
Four groups of equal no difference of science of statistics on age, gender, coincident with severity degree of condition（P ﹥ 0.05）.
1.2 therapy A group intravenous drip Oxymatrine Injections 0.6g100ml/d；B group intravenous drip compounds are sweet
Oxalic acid glycoside injection liquid 120mg/d；C groups give intravenous drip Oxymatrine Injection 0.6g100ml/d, compound glycyrrhizin note
Penetrate liquid 120mg/d；It is oral that control group awards levocetirizine capsule 5mg；Four groups coordinate Triamcinolone acetonide benefit chaff azoles emulsifiable paste simultaneously
External application, it is as a treatment course with 2 weeks, after the course for the treatment of after carry out efficacy determination.Respectively at the first visit same day and treatment after two weeks to suffering from
Person's sings and symptoms are observed（Including itch, erythema, papule, exudation, erosion, infiltration or mossization, angling furfur etc.）, respectively
Index is pressed 4 grades of point systems in each assessment and is carried out：0=nothing, 1=slight, 2=moderate, 3=severe.Scoring is made, evaluation is treated
Effect, and observe side effect.
1.3 the standard of curative effect evaluation：Integrated value calculation formula is：Integrated value=（Product after treating 2 weeks the first visit day total ﹣ of integral
Subtotaling）/ first visit day integrates total × 100%.It cures：Integrated value reduces ＞ 95%；It is effective：Integrated value reduces 61% ~ 95%；It is good
Turn：Integrated value reduces 20 ~ 60%；Integrated value reduces ＜ 20%.
1.4 two groups of safety evaluatios check blood urine routine, biochemistry routinely with before treatment, after each course for the treatment of（Packet
Include hepatic and renal function, blood glucose, electrolyte and blood fat）, and the adverse reaction occurred during treatment is recorded, serious adverse reaction occurs and moves back
Go out observer to be judged in vain.
2 results
2 four groups of curative effect comparative examples (%) of table
A groups=Oxymatrine Treating group；B groups=SNMC in Treatment group；C groups=oxymatrine joint compound is sweet
Oxalic acid glycosides treatment group；D groups=control group.
3. 2 readme urine volume of adverse reaction A groups increase；3 appearance of B groups are weak, and slight abdominal distension, 1 hypokalemia occurs
Disease, 2 there is Mild edema symptom；C groups and D groups do not occur adverse reaction；A, two groups of B does not influence to treat.Before and after treatment
Four groups of blood urines are routinely showed no apparent exception.
3. conclusion
Oxymatrine combines SNMC in Treatment universal eczema significant effect, and effective percentage does not occur up to 100%
Adverse reaction.
Embodiment 3
Oxymatrine 200mg
Diammonium glycyrrhizinate 150mg
NaCl 0.9g
Appropriate water for injection
Every 100ml
NaCl is taken, with water for injection stirring and dissolving, oxymatrine, diammonium glycyrrhizinate is then respectively adding, continues to stir
When be completely dissolved, add and inject water to total amount, filtration to clear and bright, potting, sterilizing to get.
Embodiment 4
Oxymatrine 200g
Glycyrrhizin 150g
Sodium Hydroxymethyl Stalcs 10g
Lactose 50g
Magnesium stearate 0.5g
Appropriate pure water
It is made 1000
It by oxymatrine, glycyrrhizin, crushed 80 mesh sieve in advance, lactose taken to cross 80 mesh sieve, it is spare.Take the upper of sieving
It states fine powder to weigh by above-mentioned prescription, is uniformly mixed, mixed powder is put into mixing machine, pure water is added while stirring, stir
Softwood is made within 15 minutes, pelletizes, 50 ~ 60 DEG C of dryings of wet grain, whole grain, addition Sodium Hydroxymethyl Stalcs, magnesium stearate, mixing, tabletting,
To obtain the final product.
Embodiment 5
Oxymatrine 200mg
Diammonium glycyrrhizinate 150mg
Microcrystalline cellulose 27.5mg
Lactose fruit-appropriate hydrate
Magnesium stearate 0.5mg
Film-making
After mixing by above-mentioned raw materials, auxiliary material, it pelletizes according to conventional wet lay, dry, tabletting.
Claims (3)
1. a kind of composition is preparing the pharmaceutical composition for treating acute eczema, subacute eczema or chronic eczema acute attack
Purposes in object, which is characterized in that the composition is grouped as by following two kinds of groups：First group is divided into pharmaceutically acceptable form
Oxymatrine, second group is divided into glycyrrhizin, and the weight proportion of first component and second component is 5：1.
2. purposes according to claim 1, the wherein form of described pharmaceutical composition are injection, tablet, sustained release agent, drop
Ball, electuary, capsule, oral solution, externally used paste, emulsion.
3. purposes according to claim 1, the wherein form of described pharmaceutical composition are powder-injection, sustained release pellet.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310186782.8A CN104161763B (en) | 2013-05-20 | 2013-05-20 | A kind of pharmaceutical composition is as preparing the application treated in dermatitis and eczema |
| PCT/CN2014/073135 WO2014187185A1 (en) | 2013-05-20 | 2014-03-10 | Use of pharmaceutical composition in treating dermatitis and eczema |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310186782.8A CN104161763B (en) | 2013-05-20 | 2013-05-20 | A kind of pharmaceutical composition is as preparing the application treated in dermatitis and eczema |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104161763A CN104161763A (en) | 2014-11-26 |
| CN104161763B true CN104161763B (en) | 2018-08-07 |
Family
ID=51905889
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310186782.8A Active CN104161763B (en) | 2013-05-20 | 2013-05-20 | A kind of pharmaceutical composition is as preparing the application treated in dermatitis and eczema |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN104161763B (en) |
| WO (1) | WO2014187185A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105311043B (en) * | 2014-07-18 | 2019-03-19 | 施惠娟 | The application for preparing in drug of the composition in the preparation treatment dermotosis of metabolism disturbance |
| CN105311044B (en) * | 2014-07-18 | 2019-03-19 | 施惠娟 | A kind of pharmaceutical composition is as the application in preparation treatment cutaneous vasculitis drug |
| CN112843113B (en) * | 2021-03-23 | 2022-02-01 | 南京医科大学 | A preparation for treating contact dermatitis |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1695624A (en) * | 2004-05-12 | 2005-11-16 | 江苏恒瑞医药股份有限公司 | Combination of medication of containing kurarinone and glycyrrhetic acid, and application |
| CN101361790A (en) * | 2008-09-12 | 2009-02-11 | 中国人民武装警察部队医学院 | Medicine for treating dermatitis eczema, pruritus due to mosquito bites and use thereof |
| CN102370697A (en) * | 2011-10-27 | 2012-03-14 | 吴克 | Care cream for acute/chronic eczema and dermatitis |
| CN102973560A (en) * | 2012-12-03 | 2013-03-20 | 施惠娟 | Novel method of applying matrine to treating eczematous dermatitis |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101422474A (en) * | 2005-09-28 | 2009-05-06 | 江苏正大天晴药业股份有限公司 | Use of magnesium isoglycyrrhizinate preparation for vein in treating skin disease |
| ITRM20060163A1 (en) * | 2006-03-24 | 2007-09-25 | Ist Farmacoterapico It Spa | SPRAY COMPOSITION FOR TOPIC USE FOR THE TREATMENT AND PREVENTION OF LABIAL INFECTIONS FROM HERPES SIMPLEX |
| CN101633683B (en) * | 2008-07-26 | 2013-09-25 | 刘力 | Antihepatitis medicament, preparation method thereof and use thereof |
| CN102614213A (en) * | 2012-02-23 | 2012-08-01 | 武汉华纳联合药业有限公司 | Application of glycyrrhizic acid, glycyrrhetinic acid or salt thereof as well as gel composition and preparation method for gel composition |
| CN102772405A (en) * | 2012-08-23 | 2012-11-14 | 施惠娟 | Novel application method of treating psoriasis by matrine |
-
2013
- 2013-05-20 CN CN201310186782.8A patent/CN104161763B/en active Active
-
2014
- 2014-03-10 WO PCT/CN2014/073135 patent/WO2014187185A1/en active Application Filing
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1695624A (en) * | 2004-05-12 | 2005-11-16 | 江苏恒瑞医药股份有限公司 | Combination of medication of containing kurarinone and glycyrrhetic acid, and application |
| CN101361790A (en) * | 2008-09-12 | 2009-02-11 | 中国人民武装警察部队医学院 | Medicine for treating dermatitis eczema, pruritus due to mosquito bites and use thereof |
| CN102370697A (en) * | 2011-10-27 | 2012-03-14 | 吴克 | Care cream for acute/chronic eczema and dermatitis |
| CN102973560A (en) * | 2012-12-03 | 2013-03-20 | 施惠娟 | Novel method of applying matrine to treating eczematous dermatitis |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104161763A (en) | 2014-11-26 |
| WO2014187185A1 (en) | 2014-11-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102458156A (en) | Health food or pharmaceutical composition comprising chestnut shell extract | |
| WO2014059880A1 (en) | Method for preparation of pomegranate-peel polyphenol gel used to treat gynecological inflammation | |
| CN101708241B (en) | Medicinal composition for eliminating dampness and relieving itching | |
| CN104161763B (en) | A kind of pharmaceutical composition is as preparing the application treated in dermatitis and eczema | |
| KR102542842B1 (en) | How to relieve the symptoms of PMS | |
| EP4014999B1 (en) | Combination product containing limonin compound and sulfonylurea drug | |
| CN1250277C (en) | Medicine with antiphlogistic, analgetic, microbiostatic and diuretic effects | |
| CN102100789B (en) | Traditional Chinese medicine composition for treating pharyngitis and preparation method thereof | |
| EP4014978A1 (en) | Combination product containing limonoid and ?-glucosidase inhibitor | |
| JP7465337B2 (en) | Combination products containing limonoid compounds and SGLT-2 inhibitors | |
| CN101879169B (en) | Compound preparation for treating relevant vascular diseases and preparation method thereof | |
| CN110279866B (en) | Combination product comprising limonoids and thiazolidinediones | |
| TWI469784B (en) | Therapeutic compositoin for treating cancers | |
| CN105311044B (en) | A kind of pharmaceutical composition is as the application in preparation treatment cutaneous vasculitis drug | |
| US11040016B2 (en) | Composition for alleviating, preventing or treating female menopausal symptoms, containing, as active ingredient, pinitol, D-chiro-inositol or analog compounds thereof | |
| CN105326954A (en) | Traditional Chinese medicine composition for treating blepharitis and preparing method thereof | |
| CN105267227B (en) | A kind of pharmaceutical composition is as the application in preparation treatment sterile pustular skin disease drug | |
| CN105311043B (en) | The application for preparing in drug of the composition in the preparation treatment dermotosis of metabolism disturbance | |
| CN105311025B (en) | Kushenin and its derivative are as the application prepared in treatment sterile pustular skin disease drug | |
| US8883747B1 (en) | Topical antifungal compositions and methods of use thereof | |
| CN105709228A (en) | Medicine composition used for treating myocardial ischemia and preparation method thereof | |
| CN104161764B (en) | The application for the treatment of psoriasis is prepared containing the pharmaceutical composition of kushenin and glycyrrhizic acid | |
| CN105267228B (en) | A kind of pharmaceutical composition is as the application in preparation treatment neuropsychiatric disorders dermatoses drug | |
| CN106727605B (en) | Application of cyclovirobuxine D in preparing medicine for preventing or treating cerebral arterial thrombosis | |
| CN106265650A (en) | Ternatusine A application in preparation reduces hypoglycemic medicament |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |